Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. Jonat W, et al. Among authors: howell a. Eur J Cancer. 1996 Mar;32A(3):404-12. doi: 10.1016/0959-8049(95)00014-3. Eur J Cancer. 1996. PMID: 8814682 Clinical Trial.
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.
Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B, Forbes JF, et al. Jonat W, et al. Among authors: howell a. Eur J Cancer. 1995;31A(2):137-42. doi: 10.1016/0959-8049(94)00415-2. Eur J Cancer. 1995. PMID: 7718316 Clinical Trial.
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Buzdar A, et al. Among authors: howell a. J Clin Oncol. 1996 Jul;14(7):2000-11. doi: 10.1200/JCO.1996.14.7.2000. J Clin Oncol. 1996. PMID: 8683230 Clinical Trial.
New endocrine therapies for breast cancer.
Howell A, Downey S, Anderson E. Howell A, et al. Eur J Cancer. 1996 Apr;32A(4):576-88. doi: 10.1016/0959-8049(96)00032-9. Eur J Cancer. 1996. PMID: 8695256 Review.
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Buzdar AU, et al. Among authors: howell a. Cancer. 1998 Sep 15;83(6):1142-52. Cancer. 1998. PMID: 9740079 Clinical Trial.
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M, Cuzick J, Howell A, Jackson I; ATAC Trialists' Group. Dowsett M, et al. Among authors: howell a. Br J Cancer. 2001 Aug 3;85(3):317-24. doi: 10.1054/bjoc.2001.1925. Br J Cancer. 2001. PMID: 11487258 Free PMC article. Clinical Trial.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Baum M, et al. Among authors: howell a. Cancer. 2003 Nov 1;98(9):1802-10. doi: 10.1002/cncr.11745. Cancer. 2003. PMID: 14584060 Free article. Clinical Trial.
1,251 results